Congenital Heart Disease3DE-CHDNCT01300221
Real-time 3-Dimensional Echocardiography for Assessment of Cardiac Function and Congenital Heart Disease
An observational study of Congenital Heart Disease, run by Drexel University at 1 site in United States.
Trial summary
The propose of this study is to generate normative data of the tree-dimensional echocardiographic(3-DE) measurements for cardiac structure and function in a large cohort of normal infants, children,and adolescents. Read more about this study
- Who is it for?
- Ages 1 hour to 19 yearsHealthy volunteers can take part
- Conditions the study is for
- Congenital Heart Disease
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- Feb 2011to Mar 2011
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 hour to 19 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: Group 1. (n=300) Subjects who are healthy normal children. Group 2. (n=300) Subjects who have congenital heart disease. Group 3. (n=100) Subjects who have sickle cell disease. Group 4. (n=50) Subjects who have Duchenne muscular dystrophy. Group 5. (n=50) Subjects who have Marfan syndrome and aortic disease.
Who may be able to join
- Subjects with diagnosis that fits into Group 1 to 5 and who are willing to participate (consent/assent obtained)
- Do not meet the exclusion criteria (as follows).
Who cannot join
- Unwilling to participate or give consent.
- Clinically unstable.
- Unable to co-operate.
- Poor acoustic windows.
Trial locations and contacts
1 site in 1 country.
United States1 site
Drexel University College of Medicine/St. Christopher's Hospital for Children
Philadelphia, Pennsylvania, 19140
About this study
The propose of this study is to generate normative data of the tree-dimensional echocardiographic(3-DE) measurements for cardiac structure and function in a large cohort of normal infants, children,and adolescents. The investigators also sought to investigate the utility of 3-DE in evaluating infants, children and adolescents with congenital and acquired heart diseases.
Read the detailed description
- SPECIFIC AIMS
- To measure and calculate Z Scores of cardiac structures and function using 3-DE in a large cohort of healthy infants, children, and adolescents.
- To investigate the utility of 3-DE in infants, children and adolescents with congenital and acquired heart disease.
II. BACKGROUND AND SIGNIFICANCE
Congenital heart disease (CHD)is one of the most common congenital malformations and is associated with significant mortality and morbidity. Acquired heart diseases are also common and have significant impact on the health of the young. As the therapeutic strategies are evolving, reliable non-invasive methods to image the cardiovascular system and quantitatively assess cardiac function with accuracy and reproducibility are pivotal to define the natural history, to evaluate the results of intervention and to assess long-term outcome.Three-dimensional echocardiography (3-DE) has important clinical applications to CHD. Because of growth throughout childhood,interpretation of these measurements requires normalization of the dimensions of cardiac structures to the size of the body. This is commonly done by the calculation of Z scores for the measurement of interest. Currently available normative data in the medical literature are limited to one-dimensional and two-dimensional echocardiography measurements only.
In this study, we will generate normative data of the 3-DE measurements for cardiac structure and function in a large cohort of healthy infants, children,and adolescents. We will also investigate the utility of 3DE for assessing the cardiovascular structures and cardiac function for congenital and acquired heart disease.
III. DESIGN AND METHODS
- Subjects:
A total of 800 study subjects will be enrolled in the study after approval by the Institutional Review Board. Echocardiography data will be prospectively collected. The subjects will be divided into 5 groups:
Group 1. (n=300) Patients with normal cardiac anatomy and function by echocardiography.
Group 2. (n=300) Patients with various congenital heart diseases.
Group 3. (n=100) Patients with sickle cell disease and at risk for ventricular remodeling and pulmonary hypertension.
Group 4. (n=50) Patients with Duchenne and muscular dystrophy at risk for ventricular remodeling and dysfunction.
Group 5. (n=50) Patients with Marfan syndrome or the aortic disease.
- Procedure:
Before the study, heart rate and blood pressures will be obtained for each study subject. The subjects will be placed in a left recumbent position and ECG attached. After a complete conventional echocardiographic assessment of each subject, real-time 3-DE /Doppler study will be performed with 3-DE system. The 3-DE study will take about 30 minutes. After each study, all data will be saved and processed off line. Indication for the clinical echocardiogram will include cardiac murmur, syncope or chest pain but with a normal echocardiogram. Informed consent will be obtained from each patient and legal representatives after a full explanation of the procedure.
- Conventional echocardiography All patients will undergo a complete 2- dimensional, color flow Doppler, and spectral Doppler examination. Examination will be performed using a commercially available ultrasound system (IE33 system, Philips, Andover, Mass). All measurements will be made offline using a computer workstation(Xcelera,Philips Medical Systems,Andover,MA). All measurements will be made according to American Society of Echocardiography protocol. For any given structure, measurement will be made if excellent and unambiguous views were available.
- Transthoracic 3-DE The 3-DE/Doppler studies will be performed using the IE33 (Philips, Andover, MA,USA) ultrasound machine with X3-1 or X7-2 matrix-array transducers. The X7-2 matrix-array transducer is a new tool and particularly well suited for small children. The patient will be in a decubitus position. Image acquisition will be performed from an apical window with the LV as the region of interest based on international recommendations. To encompass the complete LV into the 3D dataset, a full volume scan will acquire in harmonic mode from four R-wave triggered subvolumes. This scan will carried out during an end-expiratory breath hold a few seconds when possible. The 3D dataset will be stored in a DICOM format on a CD-ROM and transferred to separate workstations for off-line data analysis.
- Image off-line analysis
- QLAB Semiautomated Border Detection Method:A semiautomated border detection biplane LV volume analysis was performed using off-line QLAB version 8.0 software (Philips). The LV end-diastolic volume (EDV) and end-systolic volume (ESV) (smallest LV volume) frames are identified.On both of these end-diastolic and end-systolic frames,five identification points are marked: the septal, lateral, anterior, and inferior mitral annulus and the apex (from either one of the views). Then the software automatically delineates the LV endocardial border and, by sequential analysis, creates a LV mathematical model or "cast" that represents the LV cavity.
- TomTec Semiautomated Method:LV volume analysis will be performed off-line using TomTec 4D LV-Analysis software. TomTec requires triplane manual tracing of the endocardial border after which the software selects a fitting geometric model and the total LV endocardial border is automatically delineated with possible manual corrections. Based on the six initial contours, a spatiotemporal interpolation model (like a pulsating balloon) is created by rotational and temporal interpolation of these contours. According to the initial balloon, the algorithm starts to detect the endocardial border continuously in the entire 4D dataset (without large gaps due to interpolation), like deforming the balloon in the LV until it best fits the walls in each frame. Adjustments can be made manually after this step in oblique, sagittal, and coronal planes. Subsequently, a final reconstruction of the LV model and a time-volume curve are created. LV-EDV and LV-ESV are the largest and smallest volume, respectively, from this time-volume curve.
- Data Analysis
All numerical values are expressed as mean +/- standard deviation. The real- time 3-DE measurements will be compared with other clinical data and measurements, such as cardiac catheterization or magnetic resonance imaging. Statistical significance will be defined as P<0.05. All statistical analyzes will be done using SAS for Windows version9.1 and Microsoft Excel (Microsoft Office 2007) for all analysis.
- Conditions
- Congenital Heart Disease
- Keywords
- Three dimension echocardiography, Congenital heart disease, Z-score
- Medical subject headings
- Heart Defects, Congenital
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Subjects who are healthy normal children. | |
| Group 2 | Subjects who have congenital heart disease. | |
| Group 3 | Subjects who have sickle cell disease | |
| Group 4 | Subjects who have Duchenne muscular dystrophy | |
| Group 5 | Patients who have Marfan syndrome and other aortic disease |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2011 (estimated)
- Study startFeb 2011
- Primary completionFeb 2011
- Study completionMar 2011
Why it stopped: Study did not receive IRB approval.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Congenital Heart DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Drexel University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Shuping Ge, MD, Principal investigator, Drexel University College of Medicine/St. Christopher's Hospital for Children
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01300221
- Sponsor's protocol ID
- H-16888
- Acronym
- 3DE-CHD
- Status last verified
- Sep 2013
- First submitted
- 17 Feb 2011
- Last updated
- 5 Sep 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Sep 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Real-time 3-Dimensional Echocardiography for Assessment of Cardiac Function and Congenital Heart Disease
- ClinicalTrials.gov ID
- NCT01300221
- Acronym / sponsor ID
- 3DE-CHD / H-16888
- Conditions
- Congenital Heart Disease
- Keywords
- Three dimension echocardiography, Congenital heart disease, Z-score
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: Study did not receive IRB approval.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Drexel UniversityUniversity, hospital or other
- Study start
- Feb 2011
- Primary completion
- Feb 2011 (actual)
- Study completion
- Mar 2011 (actual)
- First posted
- 21 Feb 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The propose of this study is to generate normative data of the tree-dimensional echocardiographic(3-DE) measurements for cardiac structure and function in a large cohort of normal infants, children,and adolescents. The investigators also sought to investigate the utility of 3-DE in evaluating infants, children and adolescents with congenital and acquired heart diseases.
Detailed description
- SPECIFIC AIMS
- To measure and calculate Z Scores of cardiac structures and function using 3-DE in a large cohort of healthy infants, children, and adolescents.
- To investigate the utility of 3-DE in infants, children and adolescents with congenital and acquired heart disease.
II. BACKGROUND AND SIGNIFICANCE
Congenital heart disease (CHD)is one of the most common congenital malformations and is associated with significant mortality and morbidity. Acquired heart diseases are also common and have significant impact on the health of the young. As the therapeutic strategies are evolving, reliable non-invasive methods to image the cardiovascular system and quantitatively assess cardiac function with accuracy and reproducibility are pivotal to define the natural history, to evaluate the results of intervention and to assess long-term outcome.Three-dimensional echocardiography (3-DE) has important clinical applications to CHD. Because of growth throughout childhood,interpretation of these measurements requires normalization of the dimensions of cardiac structures to the size of the body. This is commonly done by the calculation of Z scores for the measurement of interest. Currently available normative data in the medical literature are limited to one-dimensional and two-dimensional echocardiography measurements only.
In this study, we will generate normative data of the 3-DE measurements for cardiac structure and function in a large cohort of healthy infants, children,and adolescents. We will also investigate the utility of 3DE for assessing the cardiovascular structures and cardiac function for congenital and acquired heart disease.
III. DESIGN AND METHODS
- Subjects:
A total of 800 study subjects will be enrolled in the study after approval by the Institutional Review Board. Echocardiography data will be prospectively collected. The subjects will be divided into 5 groups:
Group 1. (n=300) Patients with normal cardiac anatomy and function by echocardiography.
Group 2. (n=300) Patients with various congenital heart diseases.
Group 3. (n=100) Patients with sickle cell disease and at risk for ventricular remodeling and pulmonary hypertension.
Group 4. (n=50) Patients with Duchenne and muscular dystrophy at risk for ventricular remodeling and dysfunction.
Group 5. (n=50) Patients with Marfan syndrome or the aortic disease.
- Procedure:
Before the study, heart rate and blood pressures will be obtained for each study subject. The subjects will be placed in a left recumbent position and ECG attached. After a complete conventional echocardiographic assessment of each subject, real-time 3-DE /Doppler study will be performed with 3-DE system. The 3-DE study will take about 30 minutes. After each study, all data will be saved and processed off line. Indication for the clinical echocardiogram will include cardiac murmur, syncope or chest pain but with a normal echocardiogram. Informed consent will be obtained from each patient and legal representatives after a full explanation of the procedure.
- Conventional echocardiography All patients will undergo a complete 2- dimensional, color flow Doppler, and spectral Doppler examination. Examination will be performed using a commercially available ultrasound system (IE33 system, Philips, Andover, Mass). All measurements will be made offline using a computer workstation(Xcelera,Philips Medical Systems,Andover,MA). All measurements will be made according to American Society of Echocardiography protocol. For any given structure, measurement will be made if excellent and unambiguous views were available.
- Transthoracic 3-DE The 3-DE/Doppler studies will be performed using the IE33 (Philips, Andover, MA,USA) ultrasound machine with X3-1 or X7-2 matrix-array transducers. The X7-2 matrix-array transducer is a new tool and particularly well suited for small children. The patient will be in a decubitus position. Image acquisition will be performed from an apical window with the LV as the region of interest based on international recommendations. To encompass the complete LV into the 3D dataset, a full volume scan will acquire in harmonic mode from four R-wave triggered subvolumes. This scan will carried out during an end-expiratory breath hold a few seconds when possible. The 3D dataset will be stored in a DICOM format on a CD-ROM and transferred to separate workstations for off-line data analysis.
- Image off-line analysis
- QLAB Semiautomated Border Detection Method:A semiautomated border detection biplane LV volume analysis was performed using off-line QLAB version 8.0 software (Philips). The LV end-diastolic volume (EDV) and end-systolic volume (ESV) (smallest LV volume) frames are identified.On both of these end-diastolic and end-systolic frames,five identification points are marked: the septal, lateral, anterior, and inferior mitral annulus and the apex (from either one of the views). Then the software automatically delineates the LV endocardial border and, by sequential analysis, creates a LV mathematical model or "cast" that represents the LV cavity.
- TomTec Semiautomated Method:LV volume analysis will be performed off-line using TomTec 4D LV-Analysis software. TomTec requires triplane manual tracing of the endocardial border after which the software selects a fitting geometric model and the total LV endocardial border is automatically delineated with possible manual corrections. Based on the six initial contours, a spatiotemporal interpolation model (like a pulsating balloon) is created by rotational and temporal interpolation of these contours. According to the initial balloon, the algorithm starts to detect the endocardial border continuously in the entire 4D dataset (without large gaps due to interpolation), like deforming the balloon in the LV until it best fits the walls in each frame. Adjustments can be made manually after this step in oblique, sagittal, and coronal planes. Subsequently, a final reconstruction of the LV model and a time-volume curve are created. LV-EDV and LV-ESV are the largest and smallest volume, respectively, from this time-volume curve.
- Data Analysis
All numerical values are expressed as mean +/- standard deviation. The real- time 3-DE measurements will be compared with other clinical data and measurements, such as cardiac catheterization or magnetic resonance imaging. Statistical significance will be defined as P<0.05. All statistical analyzes will be done using SAS for Windows version9.1 and Microsoft Excel (Microsoft Office 2007) for all analysis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Group 1 | – | –Subjects who are healthy normal children. |
| Group 2 | – | –Subjects who have congenital heart disease. |
| Group 3 | – | –Subjects who have sickle cell disease |
| Group 4 | – | –Subjects who have Duchenne muscular dystrophy |
| Group 5 | – | –Patients who have Marfan syndrome and other aortic disease |
Who may qualify
- Ages
- 1 hour to 19 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- Group 1. (n=300) Subjects who are healthy normal children. Group 2. (n=300) Subjects who have congenital heart disease. Group 3. (n=100) Subjects who have sickle cell disease. Group 4. (n=50) Subjects who have Duchenne muscular dystrophy. Group 5. (n=50) Subjects who have Marfan syndrome and aortic disease.
Key inclusion criteria (2 listed)
- Subjects with diagnosis that fits into Group 1 to 5 and who are willing to participate (consent/assent obtained)
- Do not meet the exclusion criteria (as follows).
Key exclusion criteria (4 listed)
- Unwilling to participate or give consent.
- Clinically unstable.
- Unable to co-operate.
- Poor acoustic windows.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Sep 2013.
Related trials for Congenital Heart Disease
Not yet recruiting
Autologous Thymus Transplant in Children With Congenital Heart Disease: A Pilot Study
Congenital Heart Disease (CHD)
RecruitingPhase 1
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
Friedreich's Ataxia (FA)
RecruitingObservational study
The CACHE Study: Coronary Artery Care in HaEmophilia
Haemophilia, Cardiovascular Diseases
RecruitingObservational study
Essen Amyloidosis Registry
Amyloidosis; Systemic, Amyloidosis Cardiac
RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Turner Syndrome, Short Stature Homeobox Gene Mutation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Shuping Ge, MD principal investigator
Drexel University College of Medicine/St. Christopher's Hospital for Children
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Congenital Heart Disease, run by Drexel University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 5 Sep 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2013.